Takeda’s new narcolepsy drug cuts cataplexy by up to 89%. Can ORZEYFUL transform treatment?
Takeda has begun selling ORZEYFUL in Japan and China, introducing the first approved orexin receptor 2 agonist for narcolepsy type 1. Two Phase 3 studies involving 273 patients demonstrated substantial improvements in wakefulness and cataplexy, while the planned US launch remains dependent on controlled-substance scheduling.